Total glucosides of paeony inhibit the inflammatory responses of mice with allergic contact dermatitis by restoring the balanced secretion of pro-/anti-inflammatory cytokines

Chun Wang, Jun Yuan, Hua Xun Wu, Yan Chang, Qingtong Wang, Yu Jing Wu, Peng Zhou, Xiao Dan Yang, Jun Yu, Wei Wei

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The present study aimed to investigate the regulation exerted by the total glucosides of paeony (TGP) on the production of interleukin-2 (IL-2), IL-4, IL-10 and IL-17 in the serum and lymphocytes of mice with allergic contact dermatitis (ACD). ACD in mice was induced by the repeated application of 2,4-dinitrochlorobenzene (DNCB) to their skins. The mice were orally administered TGP (35, 70, and 140 mg/kg/d) and prednisone (Pre, 5 mg/kg/d) from day 1 to day 7 after immunization. The inflammatory responses were evaluated by ear swelling and histological examination. Thymocyte proliferation was assayed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide assay. The cytokine production in the serum and lymphocytes supernatant was measured by enzyme-linked immunosorbent assay. The results indicated that the topical application of DNCB to the skin provoked obvious inflammatory responses. The oral administration of TGP (70 and 140 mg/kg/d) and Pre (5 mg/kg/d) significantly inhibited skin inflammation, decreased the thymus and spleen indices, and inhibited thymocyte proliferation in mice treated with DNCB. Further study indicated that TGP increased IL-4 and IL-10 production but decreased the production of IL-2 and IL-17 in the serum and lymphocyte supernatant. The correlation analysis suggested significantly positive correlations between IL-2 and IL-17 production and the severity of skin inflammation, whereas negative correlations were obtained for IL-4 and IL-10 production and skin inflammation. In summary, these results suggest that the therapeutic effects of TGP on ACD may result from its regulation of the imbalanced secretion of IL-2/IL-4 and IL-10/IL-17.

Original languageEnglish (US)
Pages (from-to)325-334
Number of pages10
JournalInternational Immunopharmacology
Volume24
Issue number2
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Paeonia
Allergic Contact Dermatitis
Glucosides
Interleukin-17
Anti-Inflammatory Agents
Dinitrochlorobenzene
Interleukin-4
Interleukin-10
Interleukin-2
Cytokines
Skin
Lymphocytes
Thymocytes
Inflammation
Serum
Therapeutic Uses
Prednisone
Thymus Gland
Ear
Oral Administration

Keywords

  • Allergic contact dermatitis
  • Interleukin-10
  • Interleukin-17
  • Interleukin-2
  • Interleukin-4
  • Total glucosides of paeony

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Total glucosides of paeony inhibit the inflammatory responses of mice with allergic contact dermatitis by restoring the balanced secretion of pro-/anti-inflammatory cytokines. / Wang, Chun; Yuan, Jun; Wu, Hua Xun; Chang, Yan; Wang, Qingtong; Wu, Yu Jing; Zhou, Peng; Yang, Xiao Dan; Yu, Jun; Wei, Wei.

In: International Immunopharmacology, Vol. 24, No. 2, 01.01.2015, p. 325-334.

Research output: Contribution to journalArticle

Wang, Chun ; Yuan, Jun ; Wu, Hua Xun ; Chang, Yan ; Wang, Qingtong ; Wu, Yu Jing ; Zhou, Peng ; Yang, Xiao Dan ; Yu, Jun ; Wei, Wei. / Total glucosides of paeony inhibit the inflammatory responses of mice with allergic contact dermatitis by restoring the balanced secretion of pro-/anti-inflammatory cytokines. In: International Immunopharmacology. 2015 ; Vol. 24, No. 2. pp. 325-334.
@article{da84af22613c4d3e927b518eca4598bb,
title = "Total glucosides of paeony inhibit the inflammatory responses of mice with allergic contact dermatitis by restoring the balanced secretion of pro-/anti-inflammatory cytokines",
abstract = "The present study aimed to investigate the regulation exerted by the total glucosides of paeony (TGP) on the production of interleukin-2 (IL-2), IL-4, IL-10 and IL-17 in the serum and lymphocytes of mice with allergic contact dermatitis (ACD). ACD in mice was induced by the repeated application of 2,4-dinitrochlorobenzene (DNCB) to their skins. The mice were orally administered TGP (35, 70, and 140 mg/kg/d) and prednisone (Pre, 5 mg/kg/d) from day 1 to day 7 after immunization. The inflammatory responses were evaluated by ear swelling and histological examination. Thymocyte proliferation was assayed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide assay. The cytokine production in the serum and lymphocytes supernatant was measured by enzyme-linked immunosorbent assay. The results indicated that the topical application of DNCB to the skin provoked obvious inflammatory responses. The oral administration of TGP (70 and 140 mg/kg/d) and Pre (5 mg/kg/d) significantly inhibited skin inflammation, decreased the thymus and spleen indices, and inhibited thymocyte proliferation in mice treated with DNCB. Further study indicated that TGP increased IL-4 and IL-10 production but decreased the production of IL-2 and IL-17 in the serum and lymphocyte supernatant. The correlation analysis suggested significantly positive correlations between IL-2 and IL-17 production and the severity of skin inflammation, whereas negative correlations were obtained for IL-4 and IL-10 production and skin inflammation. In summary, these results suggest that the therapeutic effects of TGP on ACD may result from its regulation of the imbalanced secretion of IL-2/IL-4 and IL-10/IL-17.",
keywords = "Allergic contact dermatitis, Interleukin-10, Interleukin-17, Interleukin-2, Interleukin-4, Total glucosides of paeony",
author = "Chun Wang and Jun Yuan and Wu, {Hua Xun} and Yan Chang and Qingtong Wang and Wu, {Yu Jing} and Peng Zhou and Yang, {Xiao Dan} and Jun Yu and Wei Wei",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.intimp.2014.12.026",
language = "English (US)",
volume = "24",
pages = "325--334",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Total glucosides of paeony inhibit the inflammatory responses of mice with allergic contact dermatitis by restoring the balanced secretion of pro-/anti-inflammatory cytokines

AU - Wang, Chun

AU - Yuan, Jun

AU - Wu, Hua Xun

AU - Chang, Yan

AU - Wang, Qingtong

AU - Wu, Yu Jing

AU - Zhou, Peng

AU - Yang, Xiao Dan

AU - Yu, Jun

AU - Wei, Wei

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The present study aimed to investigate the regulation exerted by the total glucosides of paeony (TGP) on the production of interleukin-2 (IL-2), IL-4, IL-10 and IL-17 in the serum and lymphocytes of mice with allergic contact dermatitis (ACD). ACD in mice was induced by the repeated application of 2,4-dinitrochlorobenzene (DNCB) to their skins. The mice were orally administered TGP (35, 70, and 140 mg/kg/d) and prednisone (Pre, 5 mg/kg/d) from day 1 to day 7 after immunization. The inflammatory responses were evaluated by ear swelling and histological examination. Thymocyte proliferation was assayed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide assay. The cytokine production in the serum and lymphocytes supernatant was measured by enzyme-linked immunosorbent assay. The results indicated that the topical application of DNCB to the skin provoked obvious inflammatory responses. The oral administration of TGP (70 and 140 mg/kg/d) and Pre (5 mg/kg/d) significantly inhibited skin inflammation, decreased the thymus and spleen indices, and inhibited thymocyte proliferation in mice treated with DNCB. Further study indicated that TGP increased IL-4 and IL-10 production but decreased the production of IL-2 and IL-17 in the serum and lymphocyte supernatant. The correlation analysis suggested significantly positive correlations between IL-2 and IL-17 production and the severity of skin inflammation, whereas negative correlations were obtained for IL-4 and IL-10 production and skin inflammation. In summary, these results suggest that the therapeutic effects of TGP on ACD may result from its regulation of the imbalanced secretion of IL-2/IL-4 and IL-10/IL-17.

AB - The present study aimed to investigate the regulation exerted by the total glucosides of paeony (TGP) on the production of interleukin-2 (IL-2), IL-4, IL-10 and IL-17 in the serum and lymphocytes of mice with allergic contact dermatitis (ACD). ACD in mice was induced by the repeated application of 2,4-dinitrochlorobenzene (DNCB) to their skins. The mice were orally administered TGP (35, 70, and 140 mg/kg/d) and prednisone (Pre, 5 mg/kg/d) from day 1 to day 7 after immunization. The inflammatory responses were evaluated by ear swelling and histological examination. Thymocyte proliferation was assayed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide assay. The cytokine production in the serum and lymphocytes supernatant was measured by enzyme-linked immunosorbent assay. The results indicated that the topical application of DNCB to the skin provoked obvious inflammatory responses. The oral administration of TGP (70 and 140 mg/kg/d) and Pre (5 mg/kg/d) significantly inhibited skin inflammation, decreased the thymus and spleen indices, and inhibited thymocyte proliferation in mice treated with DNCB. Further study indicated that TGP increased IL-4 and IL-10 production but decreased the production of IL-2 and IL-17 in the serum and lymphocyte supernatant. The correlation analysis suggested significantly positive correlations between IL-2 and IL-17 production and the severity of skin inflammation, whereas negative correlations were obtained for IL-4 and IL-10 production and skin inflammation. In summary, these results suggest that the therapeutic effects of TGP on ACD may result from its regulation of the imbalanced secretion of IL-2/IL-4 and IL-10/IL-17.

KW - Allergic contact dermatitis

KW - Interleukin-10

KW - Interleukin-17

KW - Interleukin-2

KW - Interleukin-4

KW - Total glucosides of paeony

UR - http://www.scopus.com/inward/record.url?scp=84929883945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929883945&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2014.12.026

DO - 10.1016/j.intimp.2014.12.026

M3 - Article

C2 - 25556068

AN - SCOPUS:84929883945

VL - 24

SP - 325

EP - 334

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 2

ER -